Q1 Earnings Forecast for TMDX Issued By William Blair

TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) - Research analysts at William Blair issued their Q1 2026 earnings per share estimates for TransMedics Group in a research note issued on Wednesday, July 9th. William Blair analyst R. Daniels anticipates that the company will earn $0.63 per share for the quarter. The consensus estimate for TransMedics Group's current full-year earnings is $1.00 per share. William Blair also issued estimates for TransMedics Group's Q2 2026 earnings at $0.59 EPS, Q3 2026 earnings at $0.51 EPS and Q4 2026 earnings at $0.58 EPS.

TMDX has been the topic of a number of other reports. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price target (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Oppenheimer increased their target price on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Finally, Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, TransMedics Group currently has an average rating of "Moderate Buy" and a consensus price target of $127.33.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX traded up $4.42 during midday trading on Friday, reaching $116.88. 1,284,354 shares of the company's stock traded hands, compared to its average volume of 1,360,865. The company has a market cap of $3.95 billion, a price-to-earnings ratio of 85.94 and a beta of 2.06. The company has a debt-to-equity ratio of 1.92, a quick ratio of 8.32 and a current ratio of 9.10. TransMedics Group has a one year low of $55.00 and a one year high of $177.37. The stock has a 50 day moving average of $125.49 and a 200 day moving average of $90.85.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. The firm had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The company's quarterly revenue was up 48.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.35 earnings per share.

Institutional Trading of TransMedics Group

Institutional investors have recently made changes to their positions in the business. NBC Securities Inc. purchased a new stake in shares of TransMedics Group during the first quarter worth about $25,000. Smartleaf Asset Management LLC grew its position in shares of TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock worth $30,000 after purchasing an additional 135 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new stake in shares of TransMedics Group during the fourth quarter worth about $31,000. Quarry LP grew its holdings in TransMedics Group by 88.5% during the 1st quarter. Quarry LP now owns 592 shares of the company's stock valued at $40,000 after buying an additional 278 shares in the last quarter. Finally, Hager Investment Management Services LLC grew its holdings in TransMedics Group by 38.3% during the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after buying an additional 205 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Insiders Place Their Bets

In related news, Director Edward M. Basile sold 5,000 shares of the stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the completion of the sale, the director owned 2,866 shares in the company, valued at approximately $362,405.70. This trade represents a 63.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director David Weill sold 732 shares of the stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the sale, the director owned 12,134 shares of the company's stock, valued at $1,503,159.92. This represents a 5.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 12,418 shares of company stock worth $1,512,613 over the last quarter. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.